POST-APPROVAL CHANGES IN OTC PACKAGING AND BULK TESTS THROUGH SUPAC sought by the Nonprescription Drug Manufacturers Association. Speaking at the group's annual Manufacturing Controls Seminar in Philadelphia Oct. 10-11, Manufacturing Controls Committee Chair Donald Cadge said: "It seems reasonable" that after providing and proving equivalency through FDA's Scale-Up and Post-Approval Changes guidance for immediate-release products, "it stands to reason that a company should also be able to keep all production in place but move the packaging and/or the testing of that bulk after proving equivalency." Cadge is with McNeil Consumer Products.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
At this year’s DIA China meeting, the national regulator updated its policy focus areas for this year, including clinical trial data protection and pilot projects to shorten IND approval times.
